APRINOIA Announces Approval from NMPA to Initiate Phase 3 Clin...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
SUZHOU, China, Oct. 28, 2020 /PRNewswire-AsiaNet/ -- APRINOIA Therapeutics announced today that China National Medical Products Administration (NMPA) had approved to initiate Phase 3 clinical trial to evaluate APRINOIA's positron emission tomography (PET) imaging tracer, [18F]-APN-1607, targeting ab...
Authors: LATEST ASIANET NEWS RELEASES